BioSpace News Archive

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“ Serenity ”) securityholders.

Quipt Home Medical Corp. is very pleased to announce that it has acquired NorCal Respiratory, Inc., a business with operations in California, reporting unaudited trailing 12-month annual revenues of approximately $3.2 million ‎and with anticipated Adjusted EBITDA of $650,000 post integration.

Trevi Therapeutics, Inc. today announced that Jennifer Good , President and CEO, will deliver a company presentation at 2022 BIO International Convention.

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th , 2022.

scPharmaceuticals Inc. announced that the Company has had two abstracts accepted for presentation at the American Association of Heart Failure Nurses 18th Annual Meeting, which is being held June 15-18 in Orlando, Florida.

Enlivex Therapeutics Ltd. announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.

Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) and Singular Genomics Systems, Inc. (Nasdaq: OMIC) today announced a collaboration to enable use of the Olink® Explore high-throughput proteomics platform with the Max Read kits on the Singular Genomics G4™ Sequencing Platform.

ProKidney LP, a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease, announced an update on its REGEN-007 Phase 2 clinical study of REACT™.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42nd Annual Growth Stock Conference, to be held in Chicago from June 6-9, 2022.